Home

BriaCell Therapeutics Corp. - Common Shares (BCTX)

5.0200
-0.5500 (-9.87%)

Briacell Therapeutics Corp is a biotechnology company focused on developing innovative immunotherapies to treat cancer, particularly breast cancer

The company specializes in creating personalized therapeutic approaches that harness the body’s immune system to target and eliminate cancer cells. Through its proprietary technology, Briacell aims to improve treatment outcomes for patients by enhancing the efficacy and safety of existing therapies, ultimately striving to bring new and effective cancer treatment options to the market. Their commitment to advancing cancer care is reflected in their rigorous research and clinical development efforts.

SummaryNewsPress ReleasesChartHistoricalFAQ
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administration (FDA) granted several approvals and new Fast Track designations towards the end of 2022 […]
Via FinancialNewsMedia · September 13, 2023
BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 31, 2023
BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily
CEO, William V. Williams, Reveals Game-Changing Partnership and Innovative Breakthroughs in Targeted Immunotherapies for Cancer Treatment
Via TheNewswire.com · May 30, 2023
BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 30, 2023
New Treatments May Help Those With Advanced Breast Cancer Live Longer
SPONSORED CONTENT -- (StatePoint) As of January 2023, the number of women in the United States with a history of invasive breast cancer is estimated to be 3.1 million and is expected to increase by 12% to 4 million in 2024, according to the American Cancer Society.
Via StatePoint Media · April 17, 2023
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 24, 2023 – USA News Group  –  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis. According to the American Cancer […]
Via FinancialNewsMedia · March 24, 2023
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Small and big pharma companies such as Pfizer Inc. (NYSEPFE), Celldex Therapeutics Inc. NASDAQ: CLDXNASDAQCLDX)(NASDAQ: HOLXNASDAQHOLX are ramping up efforts to help reduce or eliminate the growing breast cancer mortality rate.
Via TheNewswire.com · December 14, 2022
BriaCell’s Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs like SPDR S&P Biotech (NYSEXBI) (“XBI”) and iShares Biotechnology NASDAQ: IBBNASDAQIBB)
Via TheNewswire.com · December 2, 2022
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQIPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.
By ImmunoPrecise Antibodies · Via Business Wire · November 30, 2022
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
FN Media Group Presents USA News Group News Commentary   Vancouver, BC –December 8, 2021 – USA News Group  –  Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics. Over the past decade, cancer drug revenues increased 70%, according […]
Via FinancialNewsMedia · December 8, 2021
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent […]
Via FinancialNewsMedia · December 10, 2021
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Summer Virtual Event begins on Tuesday, August 17, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers,
By Stock News Now · Via AccessWire · August 16, 2021
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event. John Hope Bryant, guest host on CNBC and CEO of Operation HOPE will deliver the keynote to kick off the
By Access to Giving · Via AccessWire · July 8, 2021